GetTopicDetailResponse(id=3fca4e359e3, topicName=尼妥珠單抗, introduction=尼妥珠單抗, content=null, image=null, comments=2, allHits=1865, url=https://h5.medsci.cn/topic?id=47359, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=18954, tagList=[TagDto(tagId=18954, tagName=尼妥珠單抗)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2264404, encodeId=2b3822644049d, content=<a href='/topic/show?id=f38743453f7' target=_blank style='color:#2F92EE;'>#多西他賽#</a> <a href='/topic/show?id=231c10011915' target=_blank style='color:#2F92EE;'>#順鉑#</a> <a href='/topic/show?id=3fca4e359e3' target=_blank style='color:#2F92EE;'>#尼妥珠單抗#</a> <a href='/topic/show?id=7d4f239301f' target=_blank style='color:#2F92EE;'>#二期臨床試驗(yàn)#</a> <a href='/topic/show?id=71d9126e79f2' target=_blank style='color:#2F92EE;'>#復(fù)發(fā)或轉(zhuǎn)移性鼻咽癌(RM-NPC)#</a>, objectTitle=BMC Med：尼妥珠單抗聯(lián)合多西他賽和順鉑作為復(fù)發(fā)或轉(zhuǎn)移性鼻咽癌患者的一線治療：一項(xiàng)多中心、II 期臨床試驗(yàn), objectType=article, longId=875432, objectId=7f1c8e5432f6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240530/1717032442641_92910.png, objectUrl=/article/show_article.do?id=7f1c8e5432f6, replyNumber=0, likeNumber=33, createdTime=2025-05-10, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7f1c8e5432f6, moduleTitle=BMC Med：尼妥珠單抗聯(lián)合多西他賽和順鉑作為復(fù)發(fā)或轉(zhuǎn)移性鼻咽癌患者的一線治療：一項(xiàng)多中心、II 期臨床試驗(yàn), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=7f1c8e5432f6)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2130452, encodeId=21c82130452d8, content=<a href='/topic/show?id=dc29e50954f' target=_blank style='color:#2F92EE;'>#秦叔逵#</a>、<a href='/topic/show?id=9b41614554a' target=_blank style='color:#2F92EE;'>#李進(jìn)#</a>教授發(fā)現(xiàn)<a href='/topic/show?id=3fca4e359e3' target=_blank style='color:#2F92EE;'>#尼妥珠單抗#</a>聯(lián)合<a href='/topic/show?id=10dc3890e66' target=_blank style='color:#2F92EE;'>#吉西他濱#</a>可提高<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>患者療效, objectTitle=ASCO 2022：秦叔逵、李進(jìn)教授發(fā)現(xiàn)尼妥珠單抗聯(lián)合吉西他濱可提高胰腺癌患者療效, objectType=article, longId=729412, objectId=4900e294125e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20220608/60242e4ac3e24371bf3be83904cfc37c.jpg, objectUrl=/article/show_article.do?id=4900e294125e, replyNumber=0, likeNumber=178, createdTime=2023-05-06, rootId=0, userName=俠膽醫(yī)心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=4900e294125e, moduleTitle=ASCO 2022：秦叔逵、李進(jìn)教授發(fā)現(xiàn)尼妥珠單抗聯(lián)合吉西他濱可提高胰腺癌患者療效, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=4900e294125e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=887508, encodeId=4b3988e50886, content=<a href='/topic/show?id=3fca4e359e3' target=_blank style='color:#2F92EE;'>#尼妥珠單抗#</a>聯(lián)合順鉑放療改善高<a href='/topic/show?id=e151882682' target=_blank style='color:#2F92EE;'>#HIF1α#</a>表達(dá)的局部晚期<a href='/topic/show?id=f6144443e9d' target=_blank style='color:#2F92EE;'>#頭頸部鱗癌#</a>患者的預(yù)后，難以理解。HIF1確實(shí)與血管新生有關(guān)，為什么不直接關(guān)注血管，以及VEGF表達(dá)？？, objectTitle=Br J Cancer：尼妥珠單抗聯(lián)合順鉑放療改善高HIF1α表達(dá)的局部晚期頭頸部鱗癌患者的預(yù)后, objectType=article, longId=201080, objectId=d88e20108084, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020922/1600779365717_2467676.PNG, objectUrl=/article/show_article.do?id=d88e20108084, replyNumber=0, likeNumber=222, createdTime=2020-09-22, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d88e20108084, moduleTitle=Br J Cancer：尼妥珠單抗聯(lián)合順鉑放療改善高HIF1α表達(dá)的局部晚期頭頸部鱗癌患者的預(yù)后, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=d88e20108084)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話(huà)題小助手
2020-05-29
